Department of Radiology & Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
AJR Am J Roentgenol. 2021 Jan;216(1):3-19. doi: 10.2214/AJR.20.24268. Epub 2020 Nov 19.
The steadily increasing demand for diagnostic prostate MRI has led to concerns regarding the lack of access to and the availability of qualified MRI scanners and sufficiently experienced radiologists, radiographers, and technologists to meet the demand. Solutions must enhance operational benefits without compromising diagnostic performance, quality, and delivery of service. Solutions should also mitigate risks such as decreased reader confidence and referrer engagement. One approach may be the implementation of MRI without the use gadolinium-based contrast medium (bipara-metric MRI), but only if certain prerequisites such as high-quality imaging, expert interpretation quality, and availability of patient recall or on-table monitoring are mandated. Alternatively, or in combination, a clinical risk-based approach could be used for protocol selection, specifically, which biopsy-naive men need MRI with contrast medium (multiparametric MRI). There is a need for prospective studies in which biopsy decisions are made according to MRI without contrast enhancement. Such studies must define clinical and operational benefits and identify which patient groups can be scanned successfully without contrast enhancement. These higher-quality data are needed before the Prostate Imaging Reporting and Data System (PI-RADS) Committee can make evidence-based recommendations about MRI without contrast enhancement as an initial diagnostic approach for prostate cancer workup.
对前列腺 MRI 诊断的需求不断增加,这引发了人们对缺乏合格 MRI 扫描仪以及足够数量的有经验的放射科医师、放射线技师和技术员来满足需求的担忧。解决方案必须在不影响诊断性能、质量和服务提供的情况下提高运营效益。解决方案还应降低读者信心和推荐人参与度下降等风险。一种方法可能是不使用钆基造影剂(双参数 MRI)实施 MRI,但前提是必须满足某些条件,如高质量成像、专家解读质量以及患者召回或台上监测的可用性。或者,可以结合使用基于临床风险的方法来选择方案,具体来说,就是哪些没有接受过活检的男性需要使用造影剂的 MRI(多参数 MRI)。需要进行前瞻性研究,根据没有增强对比的 MRI 做出活检决策。此类研究必须定义临床和运营效益,并确定哪些患者群体可以在没有增强对比的情况下成功扫描。在前列腺成像报告和数据系统 (PI-RADS) 委员会能够就不使用造影增强作为前列腺癌检查的初始诊断方法提出基于证据的建议之前,需要这些高质量的数据。